CN1543959A - Galantamin sustained release preparation and preparing process - Google Patents
Galantamin sustained release preparation and preparing process Download PDFInfo
- Publication number
- CN1543959A CN1543959A CNA2003101157204A CN200310115720A CN1543959A CN 1543959 A CN1543959 A CN 1543959A CN A2003101157204 A CNA2003101157204 A CN A2003101157204A CN 200310115720 A CN200310115720 A CN 200310115720A CN 1543959 A CN1543959 A CN 1543959A
- Authority
- CN
- China
- Prior art keywords
- agent
- slow releasing
- releasing preparation
- galantamine
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims description 71
- 229960003980 galantamine Drugs 0.000 title claims description 40
- 238000000034 method Methods 0.000 title description 4
- 239000003405 delayed action preparation Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920001661 Chitosan Polymers 0.000 claims abstract description 6
- 229920002472 Starch Polymers 0.000 claims abstract description 6
- 235000019698 starch Nutrition 0.000 claims abstract description 6
- 239000008107 starch Substances 0.000 claims abstract description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 3
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 3
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 3
- 229940072056 alginate Drugs 0.000 claims abstract description 3
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 3
- 229920000615 alginic acid Polymers 0.000 claims abstract description 3
- 229960001631 carbomer Drugs 0.000 claims abstract description 3
- 239000004203 carnauba wax Substances 0.000 claims abstract description 3
- 229920002678 cellulose Polymers 0.000 claims abstract description 3
- 239000001913 cellulose Substances 0.000 claims abstract description 3
- 235000010980 cellulose Nutrition 0.000 claims abstract description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 3
- 239000008117 stearic acid Substances 0.000 claims abstract description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 31
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229960003943 hypromellose Drugs 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 3
- 210000000653 nervous system Anatomy 0.000 abstract description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 235000013869 carnauba wax Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Abstract
The invention relates to a Galantbaminum slow release preparation, a medicament for nervous system, and its preparation method, wherein the slow release preparation comprises 4-40mg of Galantbaminum, while the slow release base material is selected from cellulose and its derivative, alginate, chitosan, starch or its derivative, polyvinylpyrrolidone, carbomer, lactose, methyl hydroxypropylcellulose, chitosan, polyvinyl alcohol, stearic acid, glyceryl monostearate, carnauba wax, ethyl cellulose and polymethyl methacryate.
Description
Technical field:
The present invention relates to nervous system medicine galantamine slow releasing preparation and preparation method thereof.
Background technology:
Galantamine be the fifties The former Russian scholar separate the phenanthridine alkaloid that obtains from amrallid Herba Saussureae Involueratae Galanthus woronovii with Narcissus plant Narcissus spp..Along with senile dementia disease mechanism is familiar with deeply, galantamine makes further research as second filial generation cholinesterase inhibitor.U.S. Davis Bonnie took the lead in having obtained galantamine treatment alzheimer disease patent in 1987.Galantamine is ratified the back in Britain, Irish Initial Public Offering in July, 2000 by European Union, and calendar year 2001 is obtained the U.S. FDA permission and is used for the treatment of Alzheimer's disease, now 25 country's listings.Clinically be used to improve the patients with Alzheimer disease general function.This medical instrument has double action mechanism, can stimulate preferably and acetylcholine esterase inhibition, and can regulate the interior nicotine receptor site of brain, can significantly improve cognitive function light, moderate presenile dementia patient, delays the process that function of brain cell goes down.The Most patients well-tolerated, toxic and side effects is lower.The side effect of common predose or high dose for feel sick, symptoms such as vomiting, dizziness, xerostomia, after adaptation or drug withdrawal, can disappear, be not in the mood for, liver, nephrotoxicity, no carcinogenesis is so can take for a long time.The medication cycle is 2-3 month,
China the sixties from homemade pale reddish brown Bulbus Lycoridis Radiatae, the Flos Carthami Bulbus Lycoridis Radiatae separates and to obtain galantamine, the beginning is recorded in version Chinese Pharmacopoeia in 1977, uses its hydrobromate, be used for treating myasthenia gravis, the poliomyelitis sequela, postoperative myenteron paralysis, urine retention and as the antidote of curare.China ratified this medicine in 1999 and is used for benign memory deficits, improved that the patient points to that memory, learning by association, image are recalled, random shape is re-recognized and ability such as portrait memory.Now disclosed preparation has capsule, tablet, oral liquid, dispersible tablet etc., and domestic clinical using method is 4 times on the one.The galantamine ordinary preparation has common fast rise (less T in blood plasma
MaxWith higher C
Max) and the characteristics of descend fast (6-8 hour reach low ebb).Senile dementia patient's sense of independence is poor, the every day of administration for several times, and therefore the emotion that the patient easily creates antagonism reduces administration number of times, can improve the compliance that patient takes medicine, and galantamine is made slow releasing preparation, can solve this type of problem.The CA1326632 patent has been announced the manufacturing of galantamine slow releasing preparation, and Chinese patent CN99814988 discloses a kind of film controlled release preparation of making the galantamine slow releasing preparation.
The present invention has invented and has utilized the slow releasing preparation that the matrix type slow release method makes and the preparation method of this slow releasing preparation on the basis of above patented technology.Compared with prior art, easily manufactured, with low cost, effect is good, avoids medicine peak valley effect in blood plasma, and the medication number of times is reduced to 2 times on the one; Therefore, made things convenient for doctor and patient; By " pharmacoeconomics " viewpoint, reduced sunk cost, avoided the efficient resource waste.
Summary of the invention:
Slow releasing preparation of the present invention, active component galantamine chemical name is: 11-methyl-3-methoxyl group-4a, 5,9,10,11,12-six hydrogen-6H-benzofuran [3a, 3,2-ef] (2) benzo-aza-6-alcohol hydrobromate.
The invention provides a kind of new pharmaceutical preparation of galantamine, said preparation can provide the slow release of galantamine in 12 hours.
Galantamine slow releasing preparation of the present invention comprises the dosage form that tablet, capsule or other can be oral.
The present invention also provides the preparation method of galantamine slow releasing preparation.
Galantamine slow releasing preparation of the present invention comprises galantamine and sustained-release matrix and medicine acceptable carrier.
Slow releasing preparation preparation method of the present invention comprises that with galantamine and composition mix homogeneously such as suitable sustained-release matrix, diluent add binding agent to granulate, the oven dry of gained wet granular adds lubricant to a certain degree, is pressed into the tablet of suitable specification and size.
Galantamine slow releasing preparation of the present invention, the consumption of galantamine are 4mg--40mg.
Galantamine slow releasing preparation of the present invention, sustained-release matrix wherein are selected from the mixture of a kind of or its composition in cellulose and derivant, alginate, chitosan, starch and derivant thereof, polyvinylpyrrolidone, carbomer, lactose, hydroxypropyl emthylcellulose, chitosan, polyvinyl alcohol, stearic acid, glyceryl monostearate, Brazil wax, ethyl cellulose, the polymethyl methacrylate.Its consumption accounts for more than 10% (percetage by weight) of described tablet.
Consumption difference when using different slow-release material preparations.Consumptions in preparation such as slow-release material hypromellose, pregelatinized Starch, lactose are 10-90%, and polyvinylpyrrolidone is 0.5-10%.
Galantamine slow releasing preparation of the present invention, the adjuvant component of described necessity is a diluent, can be selected from the mixture of a kind of or its composition in microcrystalline Cellulose, starch, lactose, the Icing Sugar, its consumption accounts for the 1%-50% (percetage by weight) of described tablet.
Galantamine slow releasing preparation of the present invention, the adjuvant component of described necessity is a binding agent, can be selected from the mixture of hydroxypropyl emthylcellulose with adhesion characteristic, polyvinylpyrrolidone, starch, syrupy a kind of or its composition.Its consumption accounts for the 1%-20% (percetage by weight) of described tablet.
Galantamine slow releasing tablet of the present invention before being pressed into tablet, can add the pharmaceutically acceptable lubricant of effective dose, comprises the mixture of a kind of or its composition in magnesium stearate, the Pulvis Talci etc.Its consumption accounts for the 0.1%-5% (percetage by weight) of described tablet.
Galantamine slow releasing preparation of the present invention stability, release, bioavailability, aspects such as side effect, therapeutic effect all are better than prior art.
Compared with prior art, galantamine slow releasing preparation of the present invention is easily manufactured, with low cost, discharges to stablize, and effect is good, avoids medicine peak valley effect in blood plasma, and the medication number of times is reduced to 1-2 time on the one; Therefore, made things convenient for doctor and patient; By " pharmacoeconomics " viewpoint, reduced sunk cost, avoided the efficient resource waste, produced beyond thought effect.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1
Galantamin hydrobromide sustained-release sheet: 10mg/ sheet
Galanthamine hydrobromide 10.0g
Hypromellose (HPMC) 35.0g
Sodium alginate 15.0g
Pregelatinized Starch 25.0g
Lactose 20.0g
Polyvinylpyrrolidone 0.5g
Make 1000 altogether
Preparation technology: galanthamine hydrobromide, hypromellose, extra large bath acid sodium, pregelatinized Starch, lactose pulverize separately are crossed 80 mesh sieves, and mix homogeneously is that binding agent is granulated with the polyvinylpyrrolidone alcoholic solution, dry, granulate, and tabletting is promptly.
Embodiment 2
Galantamin hydrobromide sustained-release capsule: 10mg/ grain
Galanthamine hydrobromide 10.0g
Hypromellose (HPMC) 35.0g
Sodium alginate 15.0g
Pregelatinized Starch 25.0g
Lactose 20.0g
Polyvinylpyrrolidone 0.5g
Make 1000 altogether
Preparation technology: galanthamine hydrobromide, hypromellose, extra large bath acid sodium, pregelatinized Starch, lactose pulverize separately are crossed 80 mesh sieves, and mix homogeneously is that binding agent is granulated with the polyvinylpyrrolidone alcoholic solution, and dry, granulate incapsulate promptly.
Claims (10)
1, a kind of galantamine slow releasing preparation is characterized in that: comprise galantamine or its pharmaceutically acceptable salt, sustained-release matrix and/or medicine acceptable carrier.
2, slow releasing preparation according to claim 1 is characterized in that, the slow release of galantamine can be provided at least in 12 hours.
3, slow releasing preparation according to claim 1, wherein the amount of galantamine is 4-40mg.
4, slow releasing preparation according to claim 1, wherein said sustained-release matrix are selected from cellulose and derivant, alginate, chitosan, starch and derivant thereof, polyvinylpyrrolidone, carbomer, lactose, hydroxypropyl emthylcellulose, chitosan, polyvinyl alcohol, stearic acid, glyceryl monostearate, Brazil wax, ethyl cellulose, polymethyl methacrylate.
5, according to the described slow releasing preparation of claim 1-3, wherein the amount of sustained-release matrix accounts for more than 10% of described preparation.
6, slow releasing preparation according to claim 1, wherein said medicine acceptable carrier is selected from microcrystalline Cellulose, starch, lactose, Icing Sugar, hydroxypropyl emthylcellulose, polyvinylpyrrolidone.
7, slow releasing preparation according to claim 1, the amount of wherein said medicine acceptable carrier accounts for the 1-50% of described dosage form.
8, slow releasing preparation according to claim 1 is the preparation that tablet, capsule or other can be oral.
9, the slow releasing preparation of claim 1, the component that per unit dosage contains is:
Galanthamine hydrobromide 5--40mg/ agent
Hypromellose 10--90mg/ agent
Sodium alginate 10--90mg/ agent
Pregelatinized Starch 10--90mg/ agent
Lactose 10--90mg/ agent
Polyvinylpyrrolidone 0.5-10mg/ agent
10, the slow releasing preparation of claim 1, every dose of component that contains is
Galanthamine hydrobromide 10mg/ agent
Hypromellose 35mg/ agent
Sodium alginate 15mg/ agent
Pregelatinized Starch 25mg/ agent
Lactose 20mg/ agent
Polyvinylpyrrolidone 0.5mg/ agent
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310115720 CN1270717C (en) | 2003-11-28 | 2003-11-28 | Galantamin sustained release preparation and preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310115720 CN1270717C (en) | 2003-11-28 | 2003-11-28 | Galantamin sustained release preparation and preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1543959A true CN1543959A (en) | 2004-11-10 |
| CN1270717C CN1270717C (en) | 2006-08-23 |
Family
ID=34337380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310115720 Expired - Lifetime CN1270717C (en) | 2003-11-28 | 2003-11-28 | Galantamin sustained release preparation and preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270717C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099674A1 (en) * | 2004-04-14 | 2005-10-27 | Vectura Limited | Pharmaceutical compositions comprising an amphiphilic starch |
| CN101090737B (en) * | 2004-12-27 | 2010-09-08 | 卫材R&D管理有限公司 | Method for stabilizing dementia-resisting medicine |
| CN101829068A (en) * | 2010-05-06 | 2010-09-15 | 徐州市光合生物营养品有限公司 | Water soluble medicament sustained-release tablets and preparation method thereof |
| CN101947205A (en) * | 2010-07-21 | 2011-01-19 | 河南中帅医药科技发展有限公司 | Novel galanthamine sustained-release preparation and preparation method thereof |
| CN104970445A (en) * | 2015-07-21 | 2015-10-14 | 中国烟草总公司广东省公司 | Controlled-release aerosol cigarette |
-
2003
- 2003-11-28 CN CN 200310115720 patent/CN1270717C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005099674A1 (en) * | 2004-04-14 | 2005-10-27 | Vectura Limited | Pharmaceutical compositions comprising an amphiphilic starch |
| CN101090737B (en) * | 2004-12-27 | 2010-09-08 | 卫材R&D管理有限公司 | Method for stabilizing dementia-resisting medicine |
| CN101829068A (en) * | 2010-05-06 | 2010-09-15 | 徐州市光合生物营养品有限公司 | Water soluble medicament sustained-release tablets and preparation method thereof |
| CN101947205A (en) * | 2010-07-21 | 2011-01-19 | 河南中帅医药科技发展有限公司 | Novel galanthamine sustained-release preparation and preparation method thereof |
| CN101947205B (en) * | 2010-07-21 | 2013-11-27 | 河南中帅医药科技发展有限公司 | Novel galanthamine sustained-release preparation and preparation method thereof |
| CN104970445A (en) * | 2015-07-21 | 2015-10-14 | 中国烟草总公司广东省公司 | Controlled-release aerosol cigarette |
| CN104970445B (en) * | 2015-07-21 | 2017-11-07 | 中国烟草总公司广东省公司 | A kind of spacetabs type aerosol mouth cigarette |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270717C (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101073563B (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN107669687A (en) | 5 HT for body weight control2CThe modified release dosage form of activator | |
| EP0274176B1 (en) | Sustained release capsule or tablet formulation | |
| CA2563058C (en) | Supportive treatment of liver disease | |
| JPH02209A (en) | Control release compound of carbidopa/levodopa | |
| CN1270717C (en) | Galantamin sustained release preparation and preparing process | |
| CN1454054A (en) | Treating smooth muscle hyperactivity with (R)-oxybutynin and (R)-desethyloxybutynin | |
| CN104000789A (en) | Adefovir dipivoxil dispersible tablet and preparation method thereof | |
| WO2010022580A1 (en) | Medical composition for treating hyperuricemia and the use thereof | |
| WO2010022581A1 (en) | Medical composition for treating hyperuricemia and the use thereof | |
| CN108403651A (en) | dezocine oral preparation | |
| CN1247195C (en) | Silibinin oral disintegration tablet and its preparing method | |
| CN1462750A (en) | Erigeron ester B and its preparation method as well as application in pharmacy | |
| CN1927301A (en) | Tongmai Jiangzhi dispersant tablet and method for making same | |
| WO2004069246A1 (en) | Drug compositions comprising inhibitors of cholinesterase for treating senile dementia | |
| WO2008001294A2 (en) | High dose oral pharmaceutical compositions of artemether and lumefantrine | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| RU2367438C2 (en) | Controlled release trimetazidine matrix tablet | |
| CN1623548A (en) | Galanthamine slow release preparation and its preparation method | |
| CN1931140A (en) | Orally disintegrated galantamine hydrobromide tablet and its prepn process | |
| CN100484527C (en) | Sustained release formulation containing effective active component of galanthamin and its preparation process | |
| CN101947205B (en) | Novel galanthamine sustained-release preparation and preparation method thereof | |
| JPH07507280A (en) | (-)-Metriphonate-containing drugs | |
| CN104042581B (en) | Oxycodone hydrochloride sustained-release preparation and preparation method thereof | |
| CN101869708A (en) | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WU LIANG YE GROUP, YIBIN PHARMACEUTICAL CO.,LTD., Free format text: FORMER OWNER: LI SICHENG Effective date: 20080425 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080425 Address after: No. 2, middle Changjiang Road, Sichuan, Yibin Patentee after: SICHUAN YIBIN WULIANGYE GROUP YIBIN PHARMACEUTICAL Co.,Ltd. Address before: Sichuan Province, Chengdu City People's Road 4 Jinyuan Fairview Park South 8-2B Patentee before: Li Sicheng |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 644104 Binjiang East Road, Sichuan, Yibin Province Industrial Zone, No. East Road, No. 1 Patentee after: China Pharmaceutical Group Yibin Pharmaceutical Co.,Ltd. Address before: 644002 Yibin Changjiang Road, Sichuan, No. 2 Patentee before: SICHUAN YIBIN WULIANGYE GROUP YIBIN PHARMACEUTICAL Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060823 |
|
| CX01 | Expiry of patent term |